PEPDEPO
← The Bible
Metabolic small molecule

5-Amino-1MQ

An oral capsule that flips fat cells toward burning instead of storing.

Emerging evidence

Overview

5-Amino-1MQ is a small-molecule metabolic compound taken as an oral capsule. It works by inhibiting an enzyme called NNMT (nicotinamide N-methyltransferase) in fat cells. When NNMT is blocked, cellular NAD+ levels rise, which shifts how fat cells manage energy - favoring burning over storing. The tagline is accurate to the mechanism: it is trying to flip fat cells toward a more metabolically active state. This is a different approach to fat loss than GLP-1 agonists, which work through appetite suppression. 5-Amino-1MQ targets the fat cell itself at a metabolic level. It also has minor supporting roles in muscle support and energy, though fat loss is its primary application. It is a good match for people whose main goals include fat loss - often used in conjunction with a GLP-1 agonist or other metabolic support rather than as a standalone. It stacks well with semaglutide, MOTS-c, and NAD+. The oral format is a practical advantage for people who want a needle-free complement to injectable protocols. It is taken as a daily morning capsule. Dose range is 50 to 150 mg per day. Cycle length is 8 to 12 weeks. Evidence is at the emerging stage - early human data exists and it is generally well tolerated, but long-term human trials are not yet completed. It is a research compound and not FDA-approved. No specific contraindications or exclude flags are listed for it - it is not restricted by pregnancy or cancer history in the current data set. Exact dosing and whether it fits your protocol are set with a licensed provider in the PepDepo network at your consult.

At a glance

Route
Oral
Dose
50-150 mg
Frequency
Daily
Timing
Morning
Cycle
8-12 weeks

Combining

Stacks well with: Semaglutide, MOTS-c, NAD+

Safety

Early human data; generally well tolerated.

Regulatory: Research compound.

Questions

What does 5-Amino-1MQ actually do inside fat cells?

It blocks the NNMT enzyme, which raises cellular NAD+ levels. Higher NAD+ shifts fat cell metabolism toward burning energy rather than storing it.

How is it taken?

Oral capsule, taken in the morning, once daily. Doses range from 50 to 150 mg. Typical cycle length is 8 to 12 weeks.

Is it approved by the FDA?

No. It is a research compound. Early human data looks promising for tolerability, but it has not gone through FDA approval.

Can I stack it with other peptides?

It is listed as compatible with semaglutide, MOTS-c, and NAD+. No avoidWith restrictions are listed for it.

Are there any groups who should not use it?

The current data does not flag pregnancy or cancer history as contraindications for 5-Amino-1MQ. Your clinician will review your full profile at consult to confirm it is appropriate for you.

How is this different from appetite suppressants like semaglutide?

Semaglutide reduces how much you eat by signaling fullness through the GLP-1 pathway. 5-Amino-1MQ does not suppress appetite - instead it acts on the metabolism of fat cells directly, shifting them toward energy expenditure.

Want a personalized protocol?

Exact dosing is set with a licensed provider in the PepDepo network. This page is education, not a prescription.

Book a consult

Education only, not medical advice. Peptides discussed are for informational purposes and many are not FDA-approved. Eligibility, prescribing, compounding, and dispensing are handled by appropriately licensed entities. Exact protocols and dosing are set with a licensed provider in the PepDepo network at consult. Content is pending clinical review.